IT - EN
News & Announcements

News & AnnouncementsBusiness & financial news

2017, July 27 RECORDATI: VERY GOOD RESULTS AGAIN IN THE FIRST HALF 2017. CONTINUED GROWTH IN SALES +10.7%, OPERATING INCOME +19.4%, NET INCOME +19.8%.
2017, July 19 RECORDATI: THE EUROPEAN COMMISSION APPROVES REAGILA® (CARIPRAZINE) FOR THE TREATMENT OF SCHIZOPHRENIA
2017, July 7 Recordati Rare Diseases Introduces New PANHEMATIN® (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP)
2017, July 3 RECORDATI: ACQUISITION OF RIGHTS TO ASTRAZENECA'S METOPROLOL BASED TREATMENTS IN EUROPE COMPLETED
2017, June 16 RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS
2017, May 22 RECORDATI ACQUIRES RIGHTS TO ASTRAZENECA’S METOPROLOL BASED TREATMENTS IN EUROPE
2017, May 19 European CHMP Issues Positive Opinion for Cariprazine for the Treatment of Schizophrenia
2017, May 4 RECORDATI: EXCELLENT RESULTS IN THE FIRST QUARTER 2017. CONTINUED GROWTH IN SALES +13.1%, OPERATING INCOME +19.0%, NET INCOME +19.9%
2017, April 19 Recordati establishes Canadian presence with launch of Recordati Rare Diseases Canada Inc.
2017, April 13 Recordati Rare Diseases Inc. Acquires North American Marketing Rights to CYSTADANE®
2017, April 11 RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE (+16.7% vs 2015)
2017, March 1 - 12:38 RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1,153.9 MILLION (+10.1%), OPERATING INCOME € 327.4 MILLION (+17.6%) AND NET INCOME € 237.4 MILLION (+19.4%). 2016 DIVIDEND € 0.70 (+16.7%)
2017, February 27 RECORDATI: SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE
2017, February 9 RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND PROFITABILITY. NEW THREE YEAR BUSINESS PLAN PRESENTED
2017, February 1 RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN
2017, January 27 RECORDATI ANNOUNCES MARKETING APPROVAL FOR CYSTADROPS®
= price sensitive (as from 2015)